<DOC>
	<DOCNO>NCT03062280</DOCNO>
	<brief_summary>Subjects complete study DIUR-005 already complete study DIUR-003 offer opportunity either continue Chronocort® therapy switch current glucocorticoid therapy Chronocort® open-label study .</brief_summary>
	<brief_title>A Study Efficacy , Safety Tolerability Chronocort Treating CAH</brief_title>
	<detailed_description>All subject screen visit prior baseline assessment allow DIUR-006 procedure fully explain informed consent give subject . For subject DIUR-003 screen visit include safety blood test . Any subject meeting inclusion/exclusion criterion follow blood test enter study . All subject return baseline visit . For subject enter study DIUR-003 full set baseline assessment complete , include 2 blood sample ( one 09:00 one 13:00 hour ) 17-OHP A4 . For subject enter DIUR-005 , test result last visit feeder study ( Visit 4 ) use baseline assessment , 09:00 13:00 hour result take 24-hour hormone profile conduct visit . Any subject meeting inclusion/exclusion criterion follow blood test withdraw study . Once baseline assessment complete , subject give sufficient Chronocort® use next visit Week 4 . Subjects study DIUR-005 previously Chronocort® continue dose Chronocort® receive end feeder study . Subjects study DIUR-005 standard therapy subject study DIUR-003 initial dose Chronocort® determine use hydrocortisone equivalent baseline therapy . All subject return study centre 4 , 12 24 week start study DIUR-006 additional blood test dose titration , necessary . Visits thereafter take place 6-monthly interval . If change dose , interim visit need inbetween 6-monthly visit . All subject receive telephone call 3 monthly interval , unscheduled visit arrange necessary . Subjects also provide Chronocort® supply study pharmacy 3-monthly interval .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>1 . Subjects CAH successfully complete clinical trial current formulation Chronocort® . 2 . Provision sign write informed consent . 1 . Comorbid condition require daily administration medication ( use medications/supplements ) interfere metabolism glucocorticoid . 2 . Clinical biochemical evidence hepatic renal disease . Creatinine twice ULN elevate liver function test ( ALT AST &gt; 2 time ULN ] ) . 3 . Females pregnant lactating . 4 . Subjects regular daily inhale , topical , nasal oral steroid indication CAH . 5 . History malignancy ( basal cell carcinoma successfully treat &gt; 6 month prior entry study ) . 6 . Subjects history bilateral adrenalectomy . 7 . Participation another clinical trial investigational license drug device within 3 month prior inclusion study , except another clinical trial current formulation Chronocort® . 8 . Subjects unable comply requirement protocol . 9 . Subjects routinely work night shift sleep usual nighttime hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Extension study</keyword>
</DOC>